Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer

Oncogene

Volumn 35, Issue 31, 2016, Pages 4021-4035

  Van Jaarsveld, M T M ^a,b   Houthuijzen, J M ^a   Voest, E E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOCANNABINOID; FATTY ACID; G PROTEIN COUPLED RECEPTOR; ICOSANOID; LEUKOTRIENE RECEPTOR; LIPID; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHOLIPID; LYSOPHOSPHOLIPID RECEPTOR; PHOSPHOLIPID; PROSTAGLANDIN RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THROMBOXANE RECEPTOR;

CARCINOGENESIS; CLINICAL TRIAL (TOPIC); HUMAN; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR PATHOLOGY; MOLECULAR RECOGNITION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; METABOLISM; NEOPLASMS; PHYSIOLOGY;

ANIMALS; EICOSANOIDS; ENDOCANNABINOIDS; FATTY ACIDS; HUMANS; LIPIDS; LYSOPHOSPHOLIPIDS; NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LEUKOTRIENE; RECEPTORS, LYSOPHOSPHOLIPID; RECEPTORS, THROMBOXANE; SIGNAL TRANSDUCTION;

EID: 84949294378     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.467     Document Type: Review

References (346)

1. van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev 2008; 9: 112-124.
2. Czech MP, Tencerova M, Pedersen DJ, Aouadi M. Insulin signalling mechanisms for triacylglycerol storage. Diabetologia 2013; 56: 949-964.
3. Resh MD. Covalent lipid modifications of proteins. Curr Biol 2013; 23: R431-R435.
4. Houben AJ, Moolenaar WH. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev 2011; 30: 557-565.
5. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010; 10: 489-503.
6. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10: 181-193.
7. Pisanti S, Picardi P, D'Alessandro A, Laezza C, Bifulco M. The endocannabinoid signaling system in cancer. Trends Pharmacol Sci 2013; 34: 273-282.
8. Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 2011; 20: 370-383.
9. Houthuijzen JM, Daenen LG, Roodhart JM, Oosterom I, van Jaarsveld MT, Govaert KM, et al. Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response. Nat Commun 2014; 5: 5275.
10. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-873.
11. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM, Schwartz TW. Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 2009; 30: 249-259.
12. Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, et al. Crystal structure of a lipid G protein-coupled receptor. Science 2012; 335: 851-855.
13. Kuniyeda K, Okuno T, Terawaki K, Miyano M, Yokomizo T, Shimizu T. Identification of the intracellular region of the leukotriene B4 receptor type 1 that is specifically involved in Gi activation. J Biol Chem 2007; 282: 3998-4006.
14. D'Angelo DD, Eubank JJ, Davis MG, Dorn GW 2nd. Mutagenic analysis of platelet thromboxane receptor cysteines. Roles in ligand binding and receptor-effector coupling. J Biol Chem 1996; 271: 6233-6240.
15. So SP, Wu J, Huang G, Huang A, Li D, Ruan KH. Identification of residues important for ligand binding of thromboxane A2 receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach. J Biol Chem 2003; 278: 10922-10927.
16. Chiang N, Kan WM, Tai HH. Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane A2 receptor in insect cells. Arch Biochem Biophys 1996; 334: 9-17.
17. Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 1662-1667.
18. Khasawneh FT, Huang JS, Turek JW, Le Breton GC. Differential mapping of the amino acids mediating agonist and antagonist coordination with the human thromboxane A2 receptor protein. J Biol Chem 2006; 281: 26951-26965.
19. Zhou H, Yan F, Yamamoto S, Tai HH. Phenylalanine 138 in the second intracellular loop of human thromboxane receptor is critical for receptor-G-protein coupling. Biochem Biophys Res Commun 1999; 264: 171-175.
20. Chakraborty R, Pydi SP, Gleim S, Bhullar RP, Hwa J, Dakshinamurti S, et al. New insights into structural determinants for prostanoid thromboxane A2 receptor- And prostacyclin receptor-G protein coupling. Mol Cell Biol 2013; 33: 184-193.
21. Gaudreau R, Beaulieu ME, Chen Z, Le Gouill C, Lavigne P, Stankova J, et al. Structural determinants regulating expression of the high affinity leukotriene B4 receptor: involvement of dileucine motifs and alpha-helix VIII. J Biol Chem 2004; 279: 10338-10345.
22. Okuno T, Yokomizo T, Hori T, Miyano M, Shimizu T. Leukotriene B4 receptor and the function of its helix 8. J Biol Chem 2005; 280: 32049-32052.
23. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular signatures of G-protein-coupled receptors. Nature 2013; 494: 185-194.
24. Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 2013; 53: 531-556.
25. Baltoumas FA, Theodoropoulou MC, Hamodrakas SJ. Interactions of the alpha-subunits of heterotrimeric G-proteins with GPCRs, effectors and RGS proteins: a critical review and analysis of interacting surfaces, conformational shifts, structural diversity and electrostatic potentials. J Struct Biol 2013; 182: 209-218.
26. Kurose H. Galpha12 and Galpha13 as key regulatory mediator in signal transduction. Life Sci 2003; 74: 155-161.
27. Dowal L, Provitera P, Scarlata S. Stable association between G alpha(q) and phospholipase C beta 1 in living cells. J Biol Chem 2006; 281: 23999-24014.
28. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002; 296: 1636-1639.
29. Lin FT, Lai YJ, Makarova N, Tigyi G, Lin WC. The lysophosphatidic acid 2 receptor mediates down-regulation of Siva-1 to promote cell survival. J Biol Chem 2007; 282: 37759-37769.
30. Xu J, Lai YJ, Lin WC, Lin FT. TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J Biol Chem 2004; 279: 10459-10468.
31. Shuyu E, Lai YJ, Tsukahara R, Chen CS, Fujiwara Y, Yue J, et al. Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect. J Biol Chem 2009; 284: 14558-14571.
32. Brindley DN, Lin FT, Tigyi GJ. Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim Biophys Acta 2013; 1831: 74-85.
33. Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, et al. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res 2004; 64: 4209-4217.
34. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582-591.
35. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009; 15: 539-550.
36. Gotoh M, Fujiwara Y, Yue J, Liu J, Lee S, Fells J, et al. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans 2012; 40: 31-36.
37. Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, et al. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 2006; 66: 7983-7990.
38. Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006; 66: 3006-3014.
39. Samadi N, Gaetano C, Goping IS, Brindley DN. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 2009; 28: 1028-1039.
40. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev 2003; 4: 397-407.
41. Matula K, Collie-Duguid E, Murray G, Parikh K, Grabsch H, Tan P, et al. Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer 2015; 15: 762.
42. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun 2007; 363: 861-866.
43. Murakami M, Shiraishi A, Tabata K, Fujita N. Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun 2008; 371: 707-712.
44. Oka S, Ota R, Shima M, Yamashita A, Sugiura T. GPR35 is a novel lysophosphatidic acid receptor. Biochem Biophys Res Commun 2010; 395: 232-237.
45. Uhlenbrock K, Gassenhuber H, Kostenis E. Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G proteincoupled receptors. Cell Signal 2002; 14: 941-953.
46. Niedernberg A, Tunaru S, Blaukat A, Ardati A, Kostenis E. Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63. Cell Signal 2003; 15: 435-446.
47. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, et al. Lipid G protein-coupled receptor ligand identification using beta-Arrestin PathHunter assay. J Biol Chem 2009; 284: 12328-12338.
48. Zhang H, Wang D, Sun H, Hall RA, Yun CC. MAGI-3 regulates LPA-induced activation of Erk and RhoA. Cell Signal 2007; 19: 261-268.
49. Lin S, Yeruva S, He P, Singh AK, Zhang H, Chen M, et al. Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fluid absorption via LPA(5) and NHERF2. Gastroenterology 2010; 138: 649-658.
50. Varsano T, Taupin V, Guo L, Baterina Jr OY, Farquhar MG. The PDZ protein GIPC regulates trafficking of the LPA1 receptor from APPL signaling endosomes and attenuates the cell's response to LPA. PLoS One 2012; 7: e49227.
51. Yamada T, Ohoka Y, Kogo M, Inagaki S. Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs). J Biol Chem 2005; 280: 19358-19363.
52. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010; 50: 157-186.
53. Yanagida K, Kurikawa Y, Shimizu T, Ishii S. Current progress in non-Edg family LPA receptor research. Biochim Biophys Acta 2013; 1831: 33-41.
54. Chrencik JE, Roth CB, Terakado M, Kurata H, Omi R, Kihara Y, et al. Crystal structure of antagonist bound human lysophosphatidic acid receptor 1. Cell 2015; 161: 1633-1643.
55. Inagaki Y, Pham TT, Fujiwara Y, Kohno T, Osborne DA, Igarashi Y, et al. Sphingosine 1-phosphate analogue recognition and selectivity at S1P4 within the endothelial differentiation gene family of receptors. Biochem J 2005; 389: 187-195.
56. Pham TC, Fells Sr JI, Osborne DA, North EJ, Naor MM, Parrill AL. Molecular recognition in the sphingosine 1-phosphate receptor family. J Mol Graph Model 2008; 26: 1189-1201.
57. Sardar VM, Bautista DL, Fischer DJ, Yokoyama K, Nusser N, Virag T, et al. Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim Biophys Acta 2002; 1582: 309-317.
58. Fujiwara Y, Sardar V, Tokumura A, Baker D, Murakami-Murofushi K, Parrill A, et al. Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells. J Biol Chem 2005; 280: 35038-35050.
59. Parrill AL, Wang D, Bautista DL, Van Brocklyn JR, Lorincz Z, Fischer DJ, et al. Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. J Biol Chem 2000; 275: 39379-39384.
60. Wang DA, Lorincz Z, Bautista DL, Liliom K, Tigyi G, Parrill AL. A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. J Biol Chem 2001; 276: 49213-49220.
61. Fujiwara Y, Osborne DA, Walker MD, Wang DA, Bautista DA, Liliom K, et al. Identification of the hydrophobic ligand binding pocket of the S1P1 receptor. J Biol Chem 2007; 282: 2374-2385.
62. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003; 278: 25600-25606.
63. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S, et al. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther 2006; 318: 619-628.
64. Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W, et al. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem 2009; 284: 17304-17319.
65. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-Activity relationship of cloned LPA receptors. FEBS Lett 2000; 478: 159-165.
66. Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y, et al. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 2009; 284: 17731-17741.
67. Sugo T, Tachimoto H, Chikatsu T, Murakami Y, Kikukawa Y, Sato S, et al. Identification of a lysophosphatidylserine receptor on mast cells. Biochem Biophys Res Commun 2006; 341: 1078-1087.
68. Iida Y, H Tsuno N, Kishikawa J, Kaneko K, Murono K, Kawai K, et al. Lysophosphatidylserine stimulates chemotactic migration of colorectal cancer cells through GPR34 and PI3K/Akt pathway. Anticancer Res 2014; 34: 5465-5472.
69. Kitamura H, Makide K, Shuto A, Ikubo M, Inoue A, Suzuki K, et al. GPR34 is a receptor for lysophosphatidylserine with a fatty acid at the sn-2 position. J Biochem 2012; 151: 511-518.
70. Inoue A, Ishiguro J, Kitamura H, Arima N, Okutani M, Shuto A, et al. TGFalpha shedding assay: an accurate and versatile method for detecting GPCR activation. Nat Methods 2012; 9: 1021-1029.
71. Sugita K, Yamamura C, Tabata K, Fujita N. Expression of orphan G-protein coupled receptor GPR174 in CHO cells induced morphological changes and proliferation delay via increasing intracellular cAMP. Biochem Biophys Res Commun 2013; 430: 190-195.
72. Frasch SC, Berry KZ, Fernandez-Boyanapalli R, Jin HS, Leslie C, Henson PM, et al. NADPH oxidase-dependent generation of lysophosphatidylserine enhances clearance of activated and dying neutrophils via G2A. J Biol Chem 2008; 283: 33736-33749.
73. Liebscher I, Muller U, Teupser D, Engemaier E, Engel KM, Ritscher L, et al. Altered immune response in mice deficient for the G protein-coupled receptor GPR34. J Biol Chem 2011; 286: 2101-2110.
74. Ikubo M, Inoue A, Nakamura S, Jung S, Sayama M, Otani Y, et al. Structure-Activity relationships of lysophosphatidylserine analogs as agonists of G-protein-coupled receptors GPR34, P2Y10, and GPR174. J Med Chem 2015; 58: 4204-4219.
75. Uwamizu A, Inoue A, Suzuki K, Okudaira M, Shuto A, Shinjo Y, et al. Lysophosphatidylserine analogues differentially activate three LysoPS receptors. J Biochem 2015; 157: 151-160.
76. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-1101.
77. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 2007; 362: 928-934.
78. Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem 2009; 145: 13-20.
79. Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ. The GPR55 ligand L-Alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 2009; 23: 183-193.
80. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, et al. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 2009; 284: 29817-29827.
81. Xu Y, Zhu K, Hong G, Wu W, Baudhuin LM, Xiao Y, et al. Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nat Cell Biol 2000; 2: 261-267.
82. Zhu K, Baudhuin LM, Hong G, Williams FS, Cristina KL, Kabarowski JH, et al. Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J Biol Chem 2001; 276: 41325-41335.
83. Kabarowski JH, Zhu K, Le LQ, Witte ON, Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 2001; 293: 702-705.
84. Im DS, Heise CE, Nguyen T, O'Dowd BF, Lynch KR. Identification of a molecular target of psychosine and its role in globoid cell formation. J Cell Biol 2001; 153: 429-434.
85. Soga T, Ohishi T, Matsui T, Saito T, Matsumoto M, Takasaki J, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 2005; 326: 744-751.
86. Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN. Inhibition of autotaxin production or activity blocks lysophosphatidylcholineinduced migration of human breast cancer and melanoma cells. Mol Carcinog 2009; 48: 801-809.
87. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA 2006; 103: 9643-9648.
88. Glatt S, Halbauer D, Heindl S, Wernitznig A, Kozina D, Su KC, et al. hGPR87 contributes to viability of human tumor cells. Int J Cancer 2008; 122: 2008-2016.
89. Gugger M, White R, Song S, Waser B, Cescato R, Riviere P, et al. GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung. Dis Markers 2008; 24: 41-50.
90. Okazoe H, Zhang X, Liu D, Shibuya S, Ueda N, Sugimoto M, et al. Expression and Role of GPR87 in Urothelial Carcinoma of the Bladder. Int J Mol Sci 2013; 14: 12367-12379.
91. Yan M, Li H, Zhu M, Zhao F, Zhang L, Chen T, et al. G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133(+) cancer stem-like cells in hepatocellular carcinoma. PLoS One 2013; 8: e61056.
92. Zhang Y, Qian Y, Lu W, Chen X. The G protein-coupled receptor 87 is necessary for p53-dependent cell survival in response to genotoxic stress. Cancer Res 2009; 69: 6049-6056.
93. Okumura S, Baba H, Kumada T, Nanmoku K, Nakajima H, Nakane Y, et al. Cloning of a G-protein-coupled receptor that shows an activity to transform NIH3T3 cells and is expressed in gastric cancer cells. Cancer Sci 2004; 95: 131-135.
94. Marshall JC, Collins JW, Nakayama J, Horak CE, Liewehr DJ, Steinberg SM, et al. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst 2012; 104: 1306-1319.
95. Komachi M, Sato K, Tobo M, Mogi C, Yamada T, Ohta H, et al. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo. Cancer Sci 2012; 103: 1099-1104.
96. Watson C, Long JS, Orange C, Tannahill CL, Mallon E, McGlynn LM, et al. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 2010; 177: 2205-2215.
97. Kothapalli R, Kusmartseva I, Loughran TP. Characterization of a human sphingosine-1-phosphate receptor gene (S1P5) and its differential expression in LGL leukemia. Biochim Biophys Acta 2002; 1579: 117-123.
98. Yoshida Y, Nakada M, Sugimoto N, Harada T, Hayashi Y, Kita D, et al. Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. Int J Cancer 2010; 126: 2341-2352.
99. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Spingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 2005; 64: 695-705
100. Cattoretti G, Mandelbaum J, Lee N, Chaves AH, Mahler AM, Chadburn A, et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res 2009; 69: 8686-8692.
101. Hsu A, Zhang W, Lee JF, An J, Ekambaram P, Liu J, et al. Sphingosine-1-phosphate receptor-3 signaling up-regulates epidermal growth factor receptor and enhances epidermal growth factor receptor-mediated carcinogenic activities in cultured lung adenocarcinoma cells. Int J Oncol 2012; 40: 1619-1626.
102. Patmanathan SN, Yap LF, Murray PG, Paterson IC. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod. J Cell Mol Med 2015; 19: 2329-2340.
103. Ravichandran KS. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity 2011; 35: 445-455.
104. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 2014; 14: 769-785.
105. Park D, Tosello-Trampont AC, Elliott MR, Lu M, Haney LB, Ma Z, et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/ Rac module. Nature 2007; 450: 430-434.
106. Stephenson JR, Paavola KJ, Schaefer SA, Kaur B, Van Meir EG, Hall RA. Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density. J Biol Chem 2013; 288: 22248-22256.
107. Shiratsuchi T, Futamura M, Oda K, Nishimori H, Nakamura Y, Tokino T. Cloning and characterization of BAI-Associated protein 1: a PDZ domain-containing protein that interacts with BAI1. Biochem Biophys Res Commun 1998; 247: 597-604.
108. Yoshida Y, Oshika Y, Fukushima Y, Tokunaga T, Hatanaka H, Kijima H, et al. Expression of angiostatic factors in colorectal cancer. Int J Oncol 1999; 15: 1221-1225.
109. Fukushima Y, Oshika Y, Tsuchida T, Tokunaga T, Hatanaka H, Kijima H, et al. Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer. Int J Oncol 1998; 13: 967-970.
110. Lee JH, Koh JT, Shin BA, Ahn KY, Roh JH, Kim YJ, et al. Comparative study of angiostatic and anti-invasive gene expressions as prognostic factors in gastric cancer. Int J Oncol 2001; 18: 355-361.
111. Nam DH, Park K, Suh YL, Kim JH. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 2004; 11: 863-869.
112. Kaur B, Brat DJ, Calkins CC, Van Meir EG. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol 2003; 162: 19-27.
113. Cork SM, Van Meir EG. Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development. J Mol Med (Berl) 2011; 89: 743-752.
114. Hatanaka H, Oshika Y, Abe Y, Yoshida Y, Hashimoto T, Handa A, et al. Vascularization is decreased in pulmonary adenocarcinoma expressing brainspecific angiogenesis inhibitor 1 (BAI1). Int J Mol Med 2000; 5: 181-183.
115. Kudo S, Konda R, Obara W, Kudo D, Tani K, Nakamura Y, et al. Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. Oncol Rep 2007; 18: 785-791.
116. Honda Z, Nakamura M, Miki I, Minami M, Watanabe T, Seyama Y, et al. Cloning by functional expression of platelet-Activating factor receptor from guinea-pig lung. Nature 1991; 349: 342-346.
117. Izumi T, Shimizu T. Platelet-Activating factor receptor: gene expression and signal transduction. Biochim Biophys Acta 1995; 1259: 317-333.
118. Ishii S, Nagase T, Tashiro F, Ikuta K, Sato S, Waga I, et al. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-Activating factor receptor. EMBO J 1997; 16: 133-142.
119. Giaginis C, Kourou E, Giagini A, Goutas N, Patsouris E, Kouraklis G, et al. Plateletactivating factor (PAF) receptor expression is associated with histopathological stage and grade and patients' survival in gastric adenocarcinoma. Neoplasma 2014; 61: 309-317.
120. Zhang L, Wang D, Jiang W, Edwards D, Qiu W, Barroilhet LM, et al. Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium. Reprod Biol Endocrinol 2010; 8: 74.
121. Melnikova VO, Mourad-Zeidan AA, Lev DC, Bar-Eli M. Platelet-Activating factor mediates MMP-2 expression and activation via phosphorylation of cAMPresponse element-binding protein and contributes to melanoma metastasis. J Biol Chem 2006; 281: 2911-2922.
122. Aponte M, Jiang W, Lakkis M, Li MJ, Edwards D, Albitar L, et al. Activation of platelet-Activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res 2008; 68: 5839-5848.
123. Yu Y, Zhang X, Hong S, Zhang M, Cai Q, Jiang W, et al. The expression of plateletactivating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy. Br J Cancer 2014; 111: 515-524.
124. Onuchic AC, Machado CM, Saito RF, Rios FJ, Jancar S, Chammas R. Expression of PAFR as part of a prosurvival response to chemotherapy: a novel target for combination therapy in melanoma. Mediators Inflamm 2012; 2012: 175408.
125. Melnikova VO, Balasubramanian K, Villares GJ, Dobroff AS, Zigler M, Wang H, et al. Crosstalk between protease-Activated receptor 1 and platelet-Activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem 2009; 284: 28845-28855.
126. Sun L, He Z, Ke J, Li S, Wu X, Lian L, et al. PAF receptor antagonist Ginkgolide B inhibits tumourigenesis and angiogenesis in colitis-Associated cancer. Int J Clin Exp Pathol 2015; 8: 432-440.
127. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461: 1282-1286.
128. Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res 2009; 69: 2826-2832.
129. Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and western-lifestyle inflammatory diseases. Immunity 2014; 40: 833-842.
130. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014; 20: 159-166.
131. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol 2014; 121: 91-119.
132. Sawzdargo M, George SR, Nguyen T, Xu S, Kolakowski LF, O'Dowd BF. A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochem Biophys Res Commun 1997; 239: 543-547.
133. Brown AJ, Jupe S, Briscoe CP. A family of fatty acid binding receptors. DNA Cell Biol 2005; 24: 54-61.
134. Milligan G, Alvarez-Curto E, Watterson KR, Ulven T, Hudson BD. Characterising pharmacological ligands to study the long chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. Br J Pharmacol 2014; 172: 3254-3265.
135. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003; 278: 11312-11319.
136. Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun 2003; 303: 1047-1052.
137. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003; 278: 25481-25489.
138. Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, Ippolito M, et al. (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 2005; 280: 26649-26652.
139. Stoddart LA, Smith NJ, Jenkins L, Brown AJ, Milligan G. Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. J Biol Chem 2008; 283: 32913-32924.
140. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003; 278: 11303-11311.
141. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003; 422: 173-176.
142. Kotarsky K, Nilsson NE, Flodgren E, Owman C, Olde B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Biophys Res Commun 2003; 301: 406-410.
143. Srivastava A, Yano J, Hirozane Y, Kefala G, Gruswitz F, Snell G, et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 2014; 513: 124-127.
144. Sum CS, Tikhonova IG, Neumann S, Engel S, Raaka BM, Costanzi S, et al. Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem 2007; 282: 29248-29255.
145. Lin DC, Guo Q, Luo J, Zhang J, Nguyen K, Chen M, et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol 2012; 82: 843-859.
146. Tikhonova IG, Poerio E. Free fatty acid receptors: structural models and elucidation of ligand binding interactions. BMC Struct Biol 2015; 15: 16.
147. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005; 11: 90-94.
148. Hudson BD, Shimpukade B, Milligan G, Ulven T. The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120). J Biol Chem 2014; 289: 20345-20358.
149. Watson SJ, Brown AJ, Holliday ND. Differential signaling by splice variants of the human free fatty acid receptor GPR120. Mol Pharmacol 2012; 81: 631-642.
150. Wang J, Wu X, Simonavicius N, Tian H, Ling L. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem 2006; 281: 34457-34464.
151. Suzuki M, Takaishi S, Nagasaki M, Onozawa Y, Iino I, Maeda H, et al. Mediumchain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem 2013; 288: 10684-10691.
152. Nikaido Y, Koyama Y, Yoshikawa Y, Furuya T, Takeda S. Mutation analysis and molecular modeling for the investigation of ligand-binding modes of GPR84. J Biochem 2015; 157: 311-320.
153. Kebede MA, Alquier T, Latour MG, Poitout V. Lipid receptors and islet function: therapeutic implications?. Diabetes Obes Metab 2009; 11(Suppl 4): 10-20.
154. Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014; 40: 128-139.
155. Elangovan S, Pathania R, Ramachandran S, Ananth S, Padia RN, Lan L, et al. The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival. Cancer Res 2014; 74: 1166-1178.
156. Bermudez Y, Benavente CA, Meyer RG, Coyle WR, Jacobson MK, Jacobson EL. Nicotinic acid receptor abnormalities in human skin cancer: implications for a role in epidermal differentiation. PLoS One 2011; 6: e20487.
157. Tang Y, Chen Y, Jiang H, Robbins GT, Nie D. G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. Int J Cancer 2011; 128: 847-856.
158. Nehra D, Pan AH, Le HD, Fallon EM, Carlson SJ, Kalish BT, et al. Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target?. J Surg Res 2014; 188: 451-458.
159. Wu Q, Wang H, Zhao X, Shi Y, Jin M, Wan B, et al. Identification of G-proteincoupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma. Oncogene 2013; 32: 5541-5550.
160. Fukushima K, Yamasaki E, Ishii S, Tomimatsu A, Takahashi K, Hirane M, et al. Different roles of GPR120 and GPR40 in the acquisition of malignant properties in pancreatic cancer cells. Biochem Biophys Res Commun 2015; 465: 512-515.
161. Liu Z, Hopkins MM, Zhang Z, Quisenberry CB, Fix LC, Galvan BM, et al. Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells. J Pharmacol Exp Ther 2015; 352: 380-394.
162. Halder S, Kumar S, Sharma R. The therapeutic potential of GPR120: a patent review. Expert Opin Ther 2013; 23: 1581-1590.
163. Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 2015; 517: 209-213.
164. Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 1995; 270: 18910-18916.
165. Hirata M, Kakizuka A, Aizawa M, Ushikubi F, Narumiya S. Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci USA 1994; 91: 11192-11196.
166. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-Transmembrane receptor CRTH2. J Exp Med 2001; 193: 255-261.
167. Monneret G, Gravel S, Diamond M, Rokach J, Powell WS. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001; 98: 1942-1948.
168. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997; 122: 217-224.
169. Kobayashi T, Kiriyama M, Hirata T, Hirata M, Ushikubi F, Narumiya S. Identification of domains conferring ligand binding specificity to the prostanoid receptor. Studies on chimeric prostacyclin/prostaglandin D receptors. J Biol Chem 1997; 272: 15154-15160.
170. Sawyer N, Cauchon E, Chateauneuf A, Cruz RP, Nicholson DW, Metters KM, et al. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol 2002; 137: 1163-1172.
171. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000; 1483: 285-293.
172. Ungrin MD, Carriere MC, Denis D, Lamontagne S, Sawyer N, Stocco R, et al. Key structural features of prostaglandin E(2) and prostanoid analogs involved in binding and activation of the human EP(1) prostanoid receptor. Mol Pharmacol 2001; 59: 1446-1456.
173. Brink C. Structural manipulation of eicosanoid receptors and cellular signaling. Sci World J 2007; 7: 1285-1306.
174. Kobayashi T, Ushikubi F, Narumiya S. Amino acid residues conferring ligand binding properties of prostaglandin I and prostaglandin D receptors. Identification by site-directed mutagenesis. J Biol Chem 2000; 275: 24294-24303.
175. Li Y, Zhu F, Vaidehi N, Goddard WA 3rd, Sheinerman F, Reiling S, et al. Prediction of the 3D structure and dynamics of human DP G-protein coupled receptor bound to an agonist and an antagonist. J Am Chem Soc 2007; 129: 10720-10731.
176. Hata AN, Lybrand TP, Breyer RM. Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2. J Biol Chem 2005; 280: 32442-32451.
177. Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol 2008; 153(Suppl 1): S191-S199.
178. Yokoyama U, Iwatsubo K, Umemura M, Fujita T, Ishikawa Y. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev 2013; 65: 1010-1052.
179. Stillman BA, Audoly L, Breyer RM. A conserved threonine in the second extracellular loop of the human EP2 and EP4 receptors is required for ligand binding. Eur J Pharmacol 1998; 357: 73-82.
180. Zare B, Madadkar-Sobhani A, Dastmalchi S, Mahmoudian M. Prediction of the human EP1 receptor binding site by homology modeling and molecular dynamics simulation. Sci Pharm 2011; 79: 793-816.
181. Natarajan C, Hata AN, Hamm HE, Zent R, Breyer RM. Extracellular loop II modulates GTP sensitivity of the prostaglandin EP3 receptor. Mol Pharmacol 2013; 83: 206-216.
182. Kedzie KM, Donello JE, Krauss HA, Regan JW, Gil DW. A single amino-Acid substitution in the EP2 prostaglandin receptor confers responsiveness to prostacyclin analogs. Mol Pharmacol 1998; 54: 584-590.
183. Negishi M, Irie A, Sugimoto Y, Namba T, Ichikawa A. Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of alphacarboxylic acid of agonist and arginine residue of seventh transmembrane domain. J Biol Chem 1995; 270: 16122-16127.
184. Audoly L, Breyer RM. Substitution of charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction of the prostaglandin EP3 receptor. Mol Pharmacol 1997; 51: 61-68.
185. Huang C, Tai HH. Expression and site-directed mutagenesis of mouse prostaglandin E2 receptor EP3 subtype in insect cells. Biochem J 1995; 307(Pt 2): 493-498.
186. Pierce KL, Regan JW. Prostanoid receptor heterogeneity through alternative mRNA splicing. Life Sci 1998; 62: 1479-1483.
187. Yokomizo T. Two distinct leukotriene B4 receptors, BLT1 and BLT2. J Biochem 2015; 157: 65-71.
188. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000; 192: 421-432.
189. Yokomizo T, Kato K, Hagiya H, Izumi T, Shimizu T. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem 2001; 276: 12454-12459.
190. Okuno T, Iizuka Y, Okazaki H, Yokomizo T, Taguchi R, Shimizu T. 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-Trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med 2008; 205: 759-766.
191. Sabirsh A, Bywater RP, Bristulf J, Owman C, Haeggstrom JZ. Residues from transmembrane helices 3 and 5 participate in leukotriene B4 binding to BLT1. Biochemistry 2006; 45: 5733-5744.
192. Basu S, Jala VR, Mathis S, Rajagopal ST, Del Prete A, Maturu P, et al. Critical role for polar residues in coupling leukotriene B4 binding to signal transduction in BLT1. J Biol Chem 2007; 282: 10005-10017.
193. Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 1999; 56: 657-663.
194. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275: 30531-30536.
195. Nothacker HP, Wang Z, Zhu Y, Reinscheid RK, Lin SH, Civelli O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol 2000; 58: 1601-1608.
196. Dong X, Zhao Y, Huang X, Lin K, Chen J, Wei E, et al. Structure-based drug design using GPCR homology modeling: toward the discovery of novel selective CysLT2 antagonists. Eur J Med Chem 2013; 62: 754-763.
197. Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem 2013; 288: 10967-10972.
198. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 2006; 25: 4615-4627.
199. Pugliese AM, Trincavelli ML, Lecca D, Coppi E, Fumagalli M, Ferrario S, et al. Functional characterization of two isoforms of the P2Y-like receptor GPR17: [35S] GTPgammaS binding and electrophysiological studies in 1321N1 cells. Am J Physiol Cell Physiol 2009; 297: C1028-C1040.
200. Daniele S, Lecca D, Trincavelli ML, Ciampi O, Abbracchio MP, Martini C. Regulation of PC12 cell survival and differentiation by the new P2Y-like receptor GPR17. Cell Signal 2010; 22: 697-706.
201. Eberini I, Daniele S, Parravicini C, Sensi C, Trincavelli ML, Martini C, et al. In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des 2011; 25: 743-752.
202. Parravicini C, Abbracchio MP, Fantucci P, Ranghino G. Forced unbinding of GPR17 ligands from wild type and R255I mutant receptor models through a computational approach. BMC Struct Biol 2010; 10: 8.
203. Benned-Jensen T, Rosenkilde MM. Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants. Br J Pharmacol 2010; 159: 1092-1105.
204. Maekawa A, Balestrieri B, Austen KF, Kanaoka Y. GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci USA 2009; 106: 11685-11690.
205. Caffarel MM, Andradas C, Perez-Gomez E, Guzman M, Sanchez C. Cannabinoids: a new hope for breast cancer therapy?. Cancer Treat Rev 2012; 38: 911-918.
206. Kohno M, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K, et al. Identification of N-Arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem Biophys Res Commun 2006; 347: 827-832.
207. Reggio PH. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem 2010; 17: 1468-1486.
208. Poso A, Huffman JW. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. Br J Pharmacol 2008; 153: 335-346.
209. Shim JY. Understanding functional residues of the cannabinoid CB1. Curr Top Med Chem 2010; 10: 779-798.
210. Raitio KH, Salo OM, Nevalainen T, Poso A, Jarvinen T. Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands. Curr Med Chem 2005; 12: 1217-1237.
211. Ahn KH, Bertalovitz AC, Mierke DF, Kendall DA. Dual role of the second extracellular loop of the cannabinoid receptor 1: ligand binding and receptor localization. Mol Pharmacol 2009; 76: 833-842.
212. Marcu J, Shore DM, Kapur A, Trznadel M, Makriyannis A, Reggio PH, et al. Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2. J Pharmacol Exp Ther 2013; 345: 189-197.
213. Hurst DP, Grossfield A, Lynch DL, Feller S, Romo TD, Gawrisch K, et al. A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem 2010; 285: 17954-17964.
214. Song M, Nishihara R, Wu K, Qian ZR, Kim SA, Sukawa Y, et al. Marine omega-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability. J Natl Cancer Inst 2015; 107; pii: djv007; doi: 10.1093/jnci/ djv007.
215. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual antiinflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349-361.
216. Hong S, Lu Y. Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: targeting novel lipid mediator pathways in mitigation of acute kidney injury. Front Immunol 2013; 4: 13.
217. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 447: 869-874.
218. Maddox JF, Hachicha M, Takano T, Petasis NA, Fokin VV, Serhan CN. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem 1997; 272: 6972-6978.
219. Gronert K, Martinsson-Niskanen T, Ravasi S, Chiang N, Serhan CN. Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-Triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol 2001; 158: 3-9.
220. Serhan CN, Krishnamoorthy S, Recchiuti A, Chiang N. Novel anti-inflammatory-pro-resolving mediators and their receptors. Curr Top Med Chem 2011; 11: 629-647.
221. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci USA 2010; 107: 1660-1665.
222. Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol 2012; 180: 2018-2027.
223. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005; 201: 713-722.
224. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 2007; 178: 3912-3917.
225. Bena S, Brancaleone V, Wang JM, Perretti M, Flower RJ. Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling. J Biol Chem 2012; 287: 24690-24697.
226. Cash JL, Norling LV, Perretti M. Resolution of inflammation: targeting GPCRs that interact with lipids and peptides. Drug Discov Today 2014; 19: 1186-1192.
227. Guo Y, Zhang W, Giroux C, Cai Y, Ekambaram P, Dilly AK, et al. Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid. J Biol Chem 2011; 286: 33832-33840.
228. Hosoi T, Koguchi Y, Sugikawa E, Chikada A, Ogawa K, Tsuda N, et al. Identification of a novel human eicosanoid receptor coupled to G(i/o). J Biol Chem 2002; 277: 31459-31465.
229. Hosoi T, Sugikawa E, Chikada A, Koguchi Y, Ohnuki T. TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis. Biochem Biophys Res Commun 2005; 334: 987-995.
230. Jones CE, Holden S, Tenaillon L, Bhatia U, Seuwen K, Tranter P, et al. Expression and characterization of a 5-oxo-6E, 8Z, 11Z, 14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils. Mol Pharmacol 2003; 63: 471-477.
231. Koike D, Obinata H, Yamamoto A, Takeda S, Komori H, Nara F, et al. 5-Oxo-eicosatetraenoic acid-induced chemotaxis: identification of a responsible receptor hGPCR48 and negative regulation by G protein G(12/13). J Biochem 2006; 139: 543-549.
232. Sales KJ, Milne SA, Williams AR, Anderson RA, Jabbour HN. Expression, localization, and signaling of prostaglandin F2 alpha receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-Activated protein kinase signaling pathways. J Clin Endocrinol Metab 2004; 89: 986-993.
233. Akiyama K, Ohga N, Maishi N, Hida Y, Kitayama K, Kawamoto T, et al. The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma. Pathol Int 2013; 63: 37-44.
234. Romanuik TL, Wang G, Morozova O, Delaney A, Marra MA, Sadar MD. LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med Genomics 2010; 3: 43.
235. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Lonnroth C, et al. Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol 2007; 46: 1107-1112.
236. Pradhan MP, Desai A, Palakal MJ. Systems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinoma. Syst Biol 2013; 7: 141.
237. Chen YC, Huang RL, Huang YK, Liao YP, Su PH, Wang HC, et al. Methylomics analysis identifies epigenetically silenced genes and implies an activation of beta-catenin signaling in cervical cancer. Int J Cancer 2014; 135: 117-127.
238. Spisak S, Kalmar A, Galamb O, Wichmann B, Sipos F, Peterfia B, et al. Genome-wide screening of genes regulated by DNA methylation in colon cancer development. PLoS One 2012; 7: e46215.
239. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 2011; 17: 5582-5592.
240. Shen M, Zheng T, Lan Q, Zhang Y, Hosgood HD 3rd, Zahm SH, et al. Polymorphisms in integrin genes and lymphoma risk. Leuk Res 2011; 35: 968-970.
241. Alaa M, Suzuki M, Yoshino M, Tian L, Suzuki H, Nagato K, et al. Prostaglandin E2 receptor 2 overexpression in squamous cell carcinoma of the lung correlates with p16INK4A methylation and an unfavorable prognosis. Int J Oncol 2009; 34: 805-812.
242. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, et al. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 2007; 121: 232-240.
243. Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, et al. Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Mol Cancer 2007; 6: 2.
244. Sugino Y, Misawa A, Inoue J, Kitagawa M, Hosoi H, Sugimoto T, et al. Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas. Oncogene 2007; 26: 7401-7413.
245. Catalano RD, Wilson MR, Boddy SC, McKinlay AT, Sales KJ, Jabbour HN. Hypoxia and prostaglandin E receptor 4 signalling pathways synergise to promote endometrial adenocarcinoma cell proliferation and tumour growth. PLoS One 2011; 6: e19209.
246. Huang HF, Shu P, Murphy TF, Aisner S, Fitzhugh VA, Jordan ML. Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer. Mol Cancer Res 2013; 11: 427-439.
247. Rocconi RP, Kirby TO, Seitz RS, Beck R, Straughn Jr JM, Alvarez RD, et al. Lipoxygenase pathway receptor expression in ovarian cancer. Reprod Sci 2008; 15: 321-326.
248. Hennig R, Ding XZ, Tong WG, Schneider MB, Standop J, Friess H, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002; 161: 421-428.
249. Kim EY, Seo JM, Kim C, Lee JE, Lee KM, Kim JH. BLT2 promotes the invasion and metastasis of aggressive bladder cancer cells through a reactive oxygen specieslinked pathway. Free Rad Biol Med 2010; 49: 1072-1081.
250. Magnusson C, Liu J, Ehrnstrom R, Manjer J, Jirstrom K, Andersson T, et al. Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients. Int J Cancer 2011; 129: 9-22.
251. Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003; 124: 57-70.
252. Parhamifar L, Jeppsson B, Sjolander A. Activation of cPLA2 is required for leukotriene D4-induced proliferation in colon cancer cells. Carcinogenesis 2005; 26: 1988-1998.
253. Matsuyama M, Hayama T, Funao K, Kawahito Y, Sano H, Takemoto Y, et al. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncol Rep 2007; 18: 99-104.
254. Seo JM, Cho KJ, Kim EY, Choi MH, Chung BC, Kim JH. Up-regulation of BLT2 is critical for the survival of bladder cancer cells. Exp Mol Med 2011; 43: 129-137.
255. Kim H, Choi JA, Kim JH. Ras promotes transforming growth factor-beta (TGF-beta)-induced epithelial-mesenchymal transition via a leukotriene B4 receptor-2-linked cascade in mammary epithelial cells. J Biol Chem 2014; 289: 22151-22160.
256. Lee JW, Kim JH. Activation of the leukotriene B4 receptor 2-reactive oxygen species (BLT2-ROS) cascade following detachment confers anoikis resistance in prostate cancer cells. J Biol Chem 2013; 288: 30054-30063.
257. Lee JW, Kim GY, Kim JH. Androgen receptor is up-regulated by a BLT2-linked pathway to contribute to prostate cancer progression. Biochem Biophys Res Commun 2012; 420: 428-433.
258. Seo JM, Park S, Kim JH. Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through signal transducer and activator of transcription 3 (STAT3)-dependent up-regulation of matrix metalloproteinase 2. J Biol Chem 2012; 287: 13840-13849.
259. Kim EY, Seo JM, Cho KJ, Kim JH. Ras-induced invasion and metastasis are regulated by a leukotriene B4 receptor BLT2-linked pathway. Oncogene 2010; 29: 1167-1178.
260. Drost AC, Seitz G, Boehmler A, Funk M, Norz KP, Zipfel A, et al. The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 665-673.
261. Salim T, Sand-Dejmek J, Sjolander A. The inflammatory mediator leukotriene D (4) induces subcellular beta-catenin translocation and migration of colon cancer cells. Exp Cell Res 2014; 321: 255-266.
262. Kim H, Park GS, Lee JE, Kim JH. A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells. Br J Cancer 2013; 109: 351-359.
263. Parrill AL, Tigyi G. Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions. Biochim Biophys Acta 2013; 1831: 2-12.
264. Kitayama J, Shida D, Sako A, Ishikawa M, Hama K, Aoki J, et al. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 2004; 6: R640-R646.
265. Chen J, Lan T, Zhang W, Dong L, Kang N, Zhang S, et al. Feed-forward reciprocal activation of PAFR and STAT3 regulates epithelial-mesenchymal transition in non-small cell lung cancer. Cancer Res 2015; 75: 4198-4210.
266. Meisen WH, Dubin S, Sizemore ST, Mathsyaraja H, Thies K, Lehman NL, et al. Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. Mol Cancer Ther 2015; 14: 307-314.
267. Sundaram S, Ghosh J. Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. Biochem Biophys Res Commun 2006; 339: 93-98.
268. Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, Hoey T, et al. G proteincoupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci USA 2005; 102: 6027-6032.
269. Yu W, Ma S, Wang L, Zuo B, Li M, Qiao Z, et al. Upregulation of GPR34 expression affects the progression and prognosis of human gastric adenocarcinoma by PI3K/PDK1/AKT pathway. Histol Histopathol 2013; 28: 1629-1638.
270. Yun CC, Sun H, Wang D, Rusovici R, Castleberry A, Hall RA, et al. LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am J Physiol Cell Physiol 2005; 289: C2-C11.
271. Chang J, Vacher J, Yao B, Fan X, Zhang B, Harris RC, et al. Prostaglandin E receptor 4 (EP4) promotes colonic tumorigenesis. Oncotarget 2015; 6: 33500-33511.
272. Galamb O, Sipos F, Spisak S, Galamb B, Krenacs T, Valcz G, et al. Potential biomarkers of colorectal adenoma-dysplasia-carcinoma progression: mRNA expression profiling and in situ protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes. Cell Oncol 2009; 31: 19-29.
273. Tian D, Hu H, Sun Y, Tang Y, Lei M, Liu L, et al. Expression of brainspecific angiogenesis inhibitor1 and association with p53, microvessel density and vascular endothelial growth factor in the tissue of human bladder transitional cell carcinoma. Mol Med Rep 2015; 12: 4522-4529.
274. Ansell SM, Akasaka T, McPhail E, Manske M, Braggio E, Price-Troska T, et al. t(X; 14) (p11; q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood 2012; 120: 3949-3957.
275. Quint K, Stiel N, Neureiter D, Schlicker HU, Nimsky C, Ocker M, et al. The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas. Tumour Biol 2014; 35: 8979-8989.
276. Perez-Gomez E, Andradas C, Flores JM, Quintanilla M, Paramio JM, Guzman M, et al. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene 2013; 32: 2534-2542.
277. Qin Y, Verdegaal EM, Siderius M, Bebelman JP, Smit MJ, Leurs R, et al. Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target. Pigment Cell Melanoma Res 2011; 24: 207-218.
278. Kiss GN, Fells JI, Gupte R, Lee SC, Liu J, Nusser N, et al. Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol Pharmacol 2012; 82: 1162-1173.
279. Okabe K, Hayashi M, Yamawaki Y, Teranishi M, Honoki K, Mori T, et al. Possible involvement of lysophosphatidic acid receptor-5 gene in the acquisition of growth advantage of rat tumor cells. Mol Carcinog 2011; 50: 635-642.
280. Funke M, Zhao Z, Xu Y, Chun J, Tager AM. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol 2012; 46: 355-364.
281. Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, et al. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 1999; 5: 4308-4318.
282. Ishdorj G, Graham BA, Hu X, Chen J, Johnston JB, Fang X, et al. Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC. J Biol Chem 2008; 283: 16818-16829.
283. Altman MK, Gopal V, Jia W, Yu S, Hall H, Mills GB, et al. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer 2010; 9: 140.
284. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005; 280: 24053-24063.
285. Okuyama T, Ishihara S, Sato H, Rumi MA, Kawashima K, Miyaoka Y, et al. Activation of prostaglandin E2-receptor EP2 and EP4 pathways induces growth inhibition in human gastric carcinoma cell lines. J Lab Clin Med 2002; 140: 92-102.
286. Inada M, Takita M, Yokoyama S, Watanabe K, Tominari T, Matsumoto C, et al. Direct melanoma cell contact induces stromal cell autocrine prostaglandin E2-EP4 receptor signaling that drives tumor growth, angiogenesis and metastasis. J Biol Chem 2015; e-pub ahead of print 16 October 2015.
287. Huang RY, Li SS, Guo HZ, Huang Y, Zhang X, Li MY, et al. Thromboxane A2 exerts promoting effects on cell proliferation through mediating cyclooxygenase-2 signal in lung adenocarcinoma cells. J Cancer Res Clin Oncol 2014; 140: 375-386.
288. Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 2005; 65: 9304-9311.
289. Taghavi P, Verhoeven E, Jacobs JJ, Lambooij JP, Stortelers C, Tanger E, et al. In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene 2008; 27: 6806-6816.
290. Rundhaug JE, Simper MS, Surh I, Fischer SM. The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev 2011; 30: 465-480.
291. Sung YM, He G, Hwang DH, Fischer SM. Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development. Oncogene 2006; 25: 5507-5516.
292. Kastner S, Voss T, Keuerleber S, Glockel C, Freissmuth M, Sommergruber W. Expression of G protein-coupled receptor 19 in human lung cancer cells is triggered by entry into S-phase and supports G(2)-M cell-cycle progression. Mol Cancer Res 2012; 10: 1343-1358.
293. Kargl J, Andersen L, Hasenohrl C, Feuersinger D, Stancic A, Fauland A, et al. GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis. Br J Pharmacol 2015; e-pub ahead of print 5 October 2015; doi: 10.1111/bph.13345.
294. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008; 100: 1630-1642.
295. Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A, et al. Role of LPA4/ p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell 2008; 19: 5435-5445.
296. Chen M, Towers LN, O'Connor KL. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am J Physiol Cell Physiol 2007; 292: C1927-C1933.
297. Lee SC, Fujiwara Y, Liu J, Yue J, Shimizu Y, Norman DD, et al. Autotaxin, LPA receptors (1 and 5) exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis. Mol Cancer Res 2014; 13: 174-185.
298. Shida D, Fang X, Kordula T, Takabe K, Lepine S, Alvarez SE, et al. Cross-Talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res 2008; 68: 6569-6577.
299. Hayashi M, Okabe K, Kato K, Okumura M, Fukui R, Fukushima N, et al. Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells. Cancer Lett 2012; 316: 91-96.
300. Okabe K, Hayashi M, Kato K, Okumura M, Fukui R, Honoki K, et al. Lysophosphatidic acid receptor-3 increases tumorigenicity and aggressiveness of rat hepatoma RH7777 cells. Mol Carcinog 2013; 52: 247-254.
301. Jongsma M, Matas-Rico E, Rzadkowski A, Jalink K, Moolenaar WH. LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor. PLoS One 2011; 6: e29260.
302. Bai X, Wang J, Zhang L, Ma J, Zhang H, Xia S, et al. Prostaglandin E(2) receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells. Int J Oncol 2013; 42: 1833-1841.
303. Yang H, Ganguly A, Cabral F. Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J Biol Chem 2010; 285: 32242-32250.
304. Han C, Michalopoulos GK, Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 2006; 207: 261-270.
305. Liu JF, Fong YC, Chang CS, Huang CY, Chen HT, Yang WH, et al. Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol Cancer 2010; 9: 43.
306. Jiang J, Dingledine R. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther 2013; 344: 360-367.
307. Kamiyama M, Pozzi A, Yang L, DeBusk LM, Breyer RM, Lin PC. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 2006; 25: 7019-7028.
308. Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest 2012; 92: 1115-1128.
309. Yang L, Huang Y, Porta R, Yanagisawa K, Gonzalez A, Segi E, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006; 66: 9665-9672.
310. Kumar JD, Holmberg C, Kandola S, Steele I, Hegyi P, Tiszlavicz L, et al. Increased expression of chemerin in squamous esophageal cancer myofibroblasts and role in recruitment of mesenchymal stromal cells. PLoS One 2014; 9: e104877.
311. Lee HJ, Park MK, Lee EJ, Lee CH. Resolvin D1 inhibits TGF-beta1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. Int J Biochem Cell Biol 2013; 45: 2801-2807.
312. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-Associated angiogenesis and tumor growth. J Exp Med 2003; 197: 221-232.
313. Yokota Y, Inoue H, Matsumura Y, Nabeta H, Narusawa M, Watanabe A, et al. Absence of LTB4/BLT1 axis facilitates generation of mouse GM-CSF-induced long-lasting antitumor immunologic memory by enhancing innate and adaptive immune systems. Blood 2012; 120: 3444-3454.
314. Jo E, Sanna MG, Gonzalez-Cabrera PJ, Thangada S, Tigyi G, Osborne DA, et al. S1P1-selective in vivo-Active agonists from high-Throughput screening: off-Theshelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 2005; 12: 703-715.
315. van Loenen PB, de Graaf C, Verzijl D, Leurs R, Rognan D, Peters SL, et al. Agonistdependent effects of mutations in the sphingosine-1-phosphate type 1 receptor. Eur J Pharmacol 2011; 667: 105-112.
316. Elbegdorj O, Westkaemper RB, Zhang Y. A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55. J Mol Graph Model 2013; 39: 50-60.
317. Sum CS, Tikhonova IG, Costanzi S, Gershengorn MC. Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. J Biol Chem 2009; 284: 3529-3536.
318. Chillar A, Wu J, So SP, Ruan KH. Involvement of non-conserved residues important for PGE2 binding to the constrained EP3 eLP2 using NMR and sitedirected mutagenesis. FEBS Lett 2008; 582: 2863-2868.
319. Margan D, Borota A, Mracec M, Mracec M. 3D homology model of the human prostaglandin E2 receptor EP4 subtype. Rev Roum Chim 2012; 57: 39-44.
320. Neuschafer-Rube F, Engemaier E, Koch S, Boer U, Puschel GP. Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J 2003; 371: 443-449.
321. Rehwald M, Neuschafer-Rube F, de Vries C, Puschel GP. Possible role for ligand binding of histidine 81 in the second transmembrane domain of the rat prostaglandin F2alpha receptor. FEBS Lett 1999; 443: 357-362.
322. Stitham J, Stojanovic A, Merenick BL, O'Hara KA, Hwa J. The unique ligandbinding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling. J Biol Chem 2003; 278: 4250-4257.
323. Feng W, Song ZH. Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor. Biochem Pharmacol 2003; 65: 1077-1085.
324. Rhee MH, Nevo I, Bayewitch ML, Zagoory O, Vogel Z. Functional role of tryptophan residues in the fourth transmembrane domain of the CB(2) cannabinoid receptor. J Neurochem 2000; 75: 2485-2491.
325. Mercier RW, Pei Y, Pandarinathan L, Janero DR, Zhang J, Makriyannis A. hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation. Chem Biol 2010; 17: 1132-1142.
326. Ballesteros JA, Weinstein H. Integrated methods for the construction of threedimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 1995; 25: 366-428.
327. Okuno T, Ago H, Terawaki K, Miyano M, Shimizu T, Yokomizo T. Helix 8 of the leukotriene B4 receptor is required for the conformational change to the low affinity state after G-protein activation. J Biol Chem 2003; 278: 41500-41509.
328. Gaudreau R, Le Gouill C, Venne MH, Stankova J, Rola-Pleszczynski M. Threonine 308 within a putative casein kinase 2 site of the cytoplasmic tail of leukotriene B (4) receptor (BLT1) is crucial for ligand-induced, G-protein-coupled receptorspecific kinase 6-mediated desensitization. J Biol Chem 2002; 277: 31567-31576.
329. Lim HS, Park JJ, Ko K, Lee MH, Chung SK. Syntheses of sphingosine-1-phosphate analogues and their interaction with EDG/S1P receptors. Bioorg Med Chem Lett 2004; 14: 2499-2503.
330. Justus CR, Dong L, Yang LV. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors. Front Physiol 2013; 4: 354.
331. Takuwa Y, Takuwa N, Sugimoto N. The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. J Biochem 2002; 131: 767-771.
332. Zhang H, Bialkowska A, Rusovici R, Chanchevalap S, Shim H, Katz JP, et al. Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5. J Biol Chem 2007; 282: 15541-15549.
333. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006; 281: 22021-22028.
334. Graler MH, Grosse R, Kusch A, Kremmer E, Gudermann T, Lipp M. The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. J Cell Biochem 2003; 89: 507-519.
335. Singh LS, Berk M, Oates R, Zhao Z, Tan H, Jiang Y, et al. Ovarian cancer G proteincoupled receptor 1, a new metastasis suppressor gene in prostate cancer. J Natl Cancer Inst 2007; 99: 1313-1327.
336. Meyer zu Heringdorf D, Jakobs KH. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 2007; 1768: 923-940.
337. Chu ZL, Jones RM, He H, Carroll C, Gutierrez V, Lucman A, et al. A role for betacell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007; 148: 2601-2609.
338. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008; 105: 2699-2704.
339. Brown SL, Jala VR, Raghuwanshi SK, Nasser MW, Haribabu B, Richardson RM. Activation and regulation of platelet-Activating factor receptor: role of G(i) and G (q) in receptor-mediated chemotactic, cytotoxic, and cross-regulatory signals. J Immunol 2006; 177: 3242-3249.
340. Jabbour HN, Sales KJ. Prostaglandin receptor signalling and function in human endometrial pathology. Trends Endocrinol Metab 2004; 15: 398-404.
341. Carnini C, Accomazzo MR, Borroni E, Vitellaro-Zuccarello L, Durand T, Folco G, et al. Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor. FASEB J 2011; 25: 3519-3528.
342. Mellor EA, Frank N, Soler D, Hodge MR, Lora JM, Austen KF, et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R. Proc Natl Acad Sci USA 2003; 100: 11589-11593.
343. He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 2004; 429: 188-193.
344. Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 2003; 170: 4953-4962.
345. Bae YS, Park JC, He R, Ye RD, Kwak JY, Suh PG, et al. Differential signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH2 or lipoxin A4 in human neutrophils. Mol Pharmacol 2003; 64: 721-730.
346. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198: 977-985.